UPDATE: Protagonist Therapeutics (PTGX) Prices 7.5M Common Stock IPO at $12/Share, Flat with Expectations

August 11, 2016 6:33 AM EDT
Get Alerts PTGX Hot Sheet
Trade PTGX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

(Updated - August 11, 2016 8:58 AM EDT)

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) announced the pricing of its initial public offering of 7,500,000 shares of common stock, at a price to the public of $12 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market on August 11, 2016, under the symbol "PTGX." In addition, Protagonist has granted the underwriters a 30-day option to purchase up to 1,125,000 additional shares at the initial public offering price, less underwriting discounts and commissions. This offering is expected to close on August 16, 2016, subject to customary closing conditions.

NOTE: The company was recently looking at a pricing range of $11 - $13 per share.

Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 10, 2016. The offering will be made only by means of a written prospectus forming part of the effective registration statement. A copy of the final prospectus, when available, may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, copies of the preliminary prospectus relating to this offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by telephone at (800) 808-7525, ext. 4814; from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, email: Barclaysprospectus@broadridge.com; or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, or email: bmoprospectus@bmo.com.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings, IPOs

Related Entities

BMO Capital, Barclays, IPO

Add Your Comment